Literature DB >> 33399310

Performance of a True Point-of-Care Assay for HIV-1/2 Viral Load Measurement at Antenatal and Postpartum Services.

Bindiya Meggi1,2, Timothy Bollinger3, Alcina Zitha1, Chishamisso Mudenyanga3, Adolfo Vubil1, Dadirayi Mutsaka3, Carina Nhachigule1, Nedio Mabunda1, Osvaldo Loquiha3, Arne Kroidl2,4,5, Ilesh V Jani1.   

Abstract

BACKGROUND: Timely viral load (VL) results during pregnancy and the postpartum period are crucial for HIV disease management and for preventing mother-to-child transmission. Point-of-care (POC) VL testing could reduce turnaround times and streamline patient management. We evaluated the diagnostic performance of the novel m-PIMA HIV-1/2 VL assay (Abbott, Chicago, IL) in Mozambique.
SETTING: The study was conducted in prenatal and postpartum consultation rooms in 2 primary health care clinics. Sample collection and testing on m-PIMA were performed by trained nurses.
METHODS: HIV-infected pregnant and postpartum women on antiretroviral treatment (ART) or ART naive were tested using both on-site m-PIMA POC and referral laboratory-based real-time VL assays. Linear regression analysis and Bland-Altman plots were used to calculate the agreement between both.
FINDINGS: Correlation between venous blood plasma POC and plasma laboratory-based VL was strong (r2 = 0.850, P < 0.01), with good agreement between the methods [overall bias 0.202 log copies/mL (95% CI: 0.366 to 0.772 log copies/mL)]. Using the threshold of 1000 copies/mL, which is used to determine ART failure, the sensitivity and specificity of the POC VL assay were 95.0% (95% CI: 91.6% to 97.3%) and 96.5% (95% CI: 94.2% to 98.0%), respectively. The correlation coefficient between the venous and capillary sample types was 0.983 (r2 = 0.966).
CONCLUSIONS: On-site, nurse-performed POC VL testing is feasible and accurate in resource-limited primary health care settings. The operational challenge of plasma separation within clinics for POC testing was successfully overcome using minicentrifuges. The use of capillary blood could simplify the execution of the assay in a clinical environment.
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Year:  2021        PMID: 33399310     DOI: 10.1097/QAI.0000000000002621

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  1 in total

1.  Diagnostic Accuracy of the Rapid Xpert HIV-1 Viral Load XC, Xpert HIV-1 Viral Load, & m-PIMA HIV-1/2 Viral Load in South African Clinics.

Authors:  Jienchi Dorward; Jessica Naidoo; Pravikrishnen Moodley; Yukteshwar Sookrajh; Natasha Samsunder; Fathima Sayed; Nivashnee Naicker; Thomas Fanshawe; Paul K Drain; Richard J Lessells; Gail Hayward; Christopher C Butler; Nigel Garrett
Journal:  J Acquir Immune Defic Syndr       Date:  2022-06-13       Impact factor: 3.771

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.